Contrasting Qiagen N.V. (NASDAQ:QGEN) & Celyad SA (CYAD)

Celyad SA (NASDAQ: CYAD) and Qiagen N.V. (NASDAQ:QGEN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership.

Valuation & Earnings

This table compares Celyad SA and Qiagen N.V.’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Celyad SA $13.77 million 40.12 -$23.29 million N/A N/A
Qiagen N.V. $1.36 billion 5.71 $443.36 million $0.33 104.65

Qiagen N.V. has higher revenue and earnings than Celyad SA.

Institutional & Insider Ownership

4.1% of Celyad SA shares are held by institutional investors. Comparatively, 63.4% of Qiagen N.V. shares are held by institutional investors. 9.0% of Qiagen N.V. shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.


This table compares Celyad SA and Qiagen N.V.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Celyad SA N/A N/A N/A
Qiagen N.V. 5.44% 11.04% 6.53%

Volatility and Risk

Celyad SA has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500. Comparatively, Qiagen N.V. has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Celyad SA and Qiagen N.V., as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Celyad SA 0 0 1 0 3.00
Qiagen N.V. 0 7 5 0 2.42

Celyad SA currently has a consensus price target of $74.00, indicating a potential upside of 27.59%. Qiagen N.V. has a consensus price target of $32.56, indicating a potential downside of 4.37%. Given Celyad SA’s stronger consensus rating and higher possible upside, analysts clearly believe Celyad SA is more favorable than Qiagen N.V..


Qiagen N.V. beats Celyad SA on 8 of the 12 factors compared between the two stocks.

Celyad SA Company Profile

Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company’s product, C-Cure, allows the differentiation of a patient’s own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle. C-Cure consists of autologous adult stem cells guided in vitro to the cardiac lineage before implantation in the failing heart. Furthermore, the Company is involved in the field of immuno-oncology, through its subsidiary, OnCyte.

Qiagen N.V. Company Profile

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company’s automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Receive News & Ratings for Celyad SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad SA and related companies with's FREE daily email newsletter.

Leave a Reply